ライフサイエンスコーパス: specific therapy

1 cytial virus (RSV) infections remain without specific therapy.

2 we make a strong recommendation against PAH-specific therapy.

3 otype infecting strains and utilize serotype-specific therapy.

4 marker for ovarian CSCs and a target for CSC-specific therapy.

5 s counselling and encourages early, syndrome-specific therapy.

6 ence of PNH at presentation will require PNH-specific therapy.

7 last major lipoprotein disorder without any specific therapy.

8 hal complication of severe sepsis that lacks specific therapy.

9 f finasteride, the rash resolved without any specific therapy.

10 in industrially developed countries and lack specific therapy.

11 morbidity and mortality, but currently lack specific therapy.

12 is and facilitate the development of antigen-specific therapy.

13 treated and which should be monitored on no specific therapy.

14 ents with either type of PH who received PAH-specific therapy.

15 candidates in whom AKI does not resolve with specific therapy.

16 each allele might be exploitable for allele-specific therapy.

17 s, to quantify disease activity and to guide specific therapy.

18 rate diagnosis and more-timely initiation of specific therapy.

19 nked to clinical events, and the efficacy of specific therapy.

20 of cells, which could be explored for tumor-specific therapy.

21 the use of less empirical and more organism-specific therapy.

22 severe illness with excess mortality and no specific therapy.

23 TZDs, and suggests amiloride might provide a specific therapy.

24 f the airborne pathogen or the nature of any specific therapy.

25 ides opportunities for effective empiric and specific therapy.

26 es IKs and has the potential to provide gene-specific therapy.

27 dy of disease pathogenesis and the design of specific therapy.

28 by partial agonists, thus achieving response-specific therapy.

29 zed by measured covariates, are chosen for a specific therapy.

30 renders this receptor a potential target for specific therapy.

31 lications, (3) approach to diagnosis and (4) specific therapy.

32 BOS has not been improved by any specific therapy.

33 cells, and also as a potential mode of gene-specific therapy.

34 Mortality is at least 40%, and there is no specific therapy.

35 luded phenotyping is essential for phenotype-specific therapy.

36 patients who have not received prior disease-specific therapy.

37 select patients most likely to respond to a specific therapy.

38 prompted us to consider organ-targeted, cell-specific therapy.

39 therapeutics with half-lives adapted to the specific therapy.

40 o a significant delay in diagnosis and Fabry-specific therapy.

41 e differential responsiveness of patients to specific therapies.

42 ilitate the development of advanced mutation-specific therapies.

43 se diagnosis and more effective and pathogen-specific therapies.

44 tients with an HRD phenotype may help tailor specific therapies.

45 d candidates for different types of mutation-specific therapies.

46 healthcare environment and most received PH-specific therapies.

47 er properties may lead to more effective and specific therapies.

48 e development of novel stem cell and disease-specific therapies.

49 ractices and differential leukemogenicity of specific therapies.

50 ies of disease mechanisms and for developing specific therapies.

51 standardized, and there are no validated PCD-specific therapies.

52 presents an attractive target to develop CSC-specific therapies.

53 % of renal transplants per annum, and eludes specific therapies.

54 uss the possibility of developing aneuploidy-specific therapies.

55 ghts that can be rapidly translated into CSC-specific therapies.

56 low and high EUTOS score, overall and within specific therapies.

57 iology of AKI may lead to the development of specific therapies.

58 sis, prognosis, or prediction of response to specific therapies.

59 use this information to develop vascular bed-specific therapies.

60 ems that may be used to identify new subtype specific therapies.

61 ovide targets for the development of disease-specific therapies.

62 utoimmune diseases, and development of cause-specific therapies.

63 et of dSSc patients who could be targeted by specific therapies.

64 patients are likely to benefit from disease-specific therapies.

65 s in opioid abuse patterns and may guide sex-specific therapies.

66 pecific nature of TAO and the development of specific therapies.

67 poor prognosis and may influence response to specific therapies.

68 s for the development of stromal compartment-specific therapies.

69 diagnoses in the ICU, and important alcohol-specific therapies.

70 DCM, which limits the potential for disease-specific therapies.

71 enic pathways, and encourage innovative site-specific therapies.

72 th stromal cells, prognosis, and response to specific therapies.

73 rse prognostic impact and may be targeted by specific therapies.

74 predictive role of c-erbB-2 for response to specific therapies.

75 pilepsies could herald a new era of genotype-specific therapies.

76 t roles for EGFR in the response to oncogene-specific therapies.

77 s will be important in development of gender-specific therapies.

78 ia promotes the resistance of tumor cells to specific therapies.

79 whose solution underlies the development of specific therapies.

80 s are most likely to benefit or be harmed by specific therapies.

81 nd replaced with recommendations tailored to specific therapies.

82 ngestion, and whether patients are receiving specific therapies.

83 hase, in patients with PAH refractory to PAH-specific therapies.

84 of TB-IRIS and may assist the development of specific therapies.

85 nically distinct subgroups that benefit from specific therapies.

86 utations could lead to personalized mutation-specific therapies.

87 esents a potential target for tumor vascular-specific therapies.

88 progression, and they can guide in tailoring specific therapies.

89 n of the disease, paving the way for subtype-specific therapies.

90 ys as potential targets for cancer stem cell-specific therapies.

91 ng diagnostic markers and targets for cancer-specific therapies.

92 ory failure, which has high mortality and no specific therapies.

93 ry Th2 profile, indicating that this antigen-specific therapy acts by a cytokine-induced pathway.

94 Thirty-five patients received specific therapy against cryptosporidiosis ie nitozoxani

95 others patients had neither IS reduction nor specific therapy against cryptosporidiosis.

96 ents that could ultimately be used to target specific therapy against these antibodies, we characteri

97 rlying cause of disease; therefore, mutation-specific therapies aimed at restoring dystrophin protein

98 jor risk factor for kidney stones and has no specific therapy, although Oxalobacter formigenes coloni

99 ltimately will be used to direct patients to specific therapies and then to monitor treatment effecti

100 scular disease and in the design of vascular-specific therapies and tissue engineering.

101 n randomly assigned and is off treatment-arm-specific therapy and only if it is unlikely that subsequ

102 mplex diseases (that can then be targeted by specific therapies) and drug repurposing.

103 s of patients with optimal responses to more specific therapies, and development of biomarkers that i

104 There is currently no specific therapy, and our ability to predict who will de

105 A group of specific therapies are directed against the influx of in

106 Several specific therapies are directed against the influx of in

107 Antigen-specific therapies are in their infancy, but the latest

108 s have improved with better supportive care, specific therapies are limited.

109 Migraine-specific therapies are now approved for the acute treatm

110 Disease-specific therapies are reviewed.

111 with systolic dysfunction, for whom most HF-specific therapies are targeted.

112 Although preventive vaccination and specific therapies are yet to be developed, exploring th

113 udes establishing a diagnosis for diagnostic-specific therapies as well as preventive strategies for

114 ress toward clinical implementation of HMGB1-specific therapy as a means to treat APAP-ALI and other

115 to clarify the role of INCS sprays as asthma-specific therapy, as well as the role of the nasal inhal

116 There are no specific therapies available to protect individuals from

117 or complication of diabetes mellitus with no specific therapy available to date.

118 de avoidance, there is currently no allergen-specific therapy available.

119 Specific therapies based on knowledge of viral functions

120 d use of the results of such tests to direct specific therapies based on laboratory hypotheses, but w

121 ion in the development of leukemia stem cell-specific therapy by targeting SALL4.

122 Specific therapies can be developed based on such knowle

123 number of older patients, and outcomes after specific therapies can be different depending on age.

124 or oncogenic target identification such that specific therapies can be matched with individual patien

125 Cutting edge brain-specific therapies, capable of circumventing the physica

126 These disease-specific therapies combined with novel therapies to acce

127 or patients who received assay-directed site-specific therapy compares favorably with previous result

128 ilored" or "personalized" medicine, in which specific therapies could be prescribed based on a patien

129 within the broad spectrum of COPD, targeted specific therapies could improve disease management.

130 ry tumour and development of a tailored site-specific therapy could improve the survival of these pat

131 ets for treating ALI, for which there are no specific therapies currently available.

132 dase A replacement therapy--the only disease-specific therapy currently available for Fabry disease--

133 se genetic data have implications for allele-specific therapy currently being developed for PXE.

134 testinal reasons for hospitalization with no specific therapy currently.

135 l resuscitation (CCR) represents a bundle of specific therapies designed to enhance perfusion during

136 ific risks, the potential application of sex-specific therapy designed to avoid poor long-term advers

137 These findings provoke pursuing specific therapies directed at correcting the underlying

138 Given pathophysiology of stroke, site-specific therapy directed at left atrial appendage occlu

139 g additional pulmonary arterial hypertension-specific therapy discontinued study treatment; survival

140 n about chronic disease pathogenesis, and no specific therapies exist for acute or chronic CHIKV dise

141 ll potential commercial market, few, if any, specific therapies exist for these conditions.

142 rms of cardiomyopathy, and no proven disease-specific therapies exist yet.

143 orly understood, and no approved vaccines or specific therapies exist.

144 specific subsets of breast tumors for which specific therapies exist.

145 of toxicity is only partially known, and no specific therapy exists for sulfide poisoning.

146 cific aortic valve stenosis, but no approved specific therapy exists to substantially lower Lp(a) con

147 C3G) is a severe kidney disease for which no specific therapy exists.

148 Currently, there are no specific therapies for AML1-ETO-positive AML.

149 or receptor (CD74) may provide new, targeted specific therapies for androgen-independent prostate can

150 may have therapeutic applications as target-specific therapies for cancer.

151 These results will help to develop mutation-specific therapies for children and adults suffering fro

152 ucture, but also suggest that development of specific therapies for CRPC should take account of targe

153 As there are no specific therapies for JEB, we tested whether a protein

154 TM function or may be exploited by designing specific therapies for MCL cases with p53 aberrations.

155 These results thus support a role for T cell-specific therapies for myocarditis.

156 nergy sensing and energy balance may lead to specific therapies for obesity and diabetes and for thei

157 rhythmias could influence the development of specific therapies for other forms of supraventricular a

158 ng is the next challenge, to enable genotype-specific therapies for patients with AML and other malig

159 d vascular morbidity in diabetes and suggest specific therapies for patients with insulin resistance

160 tery disease/myocardiaI infarction, and gene-specific therapies for patients.

161 ed treatments and the development of disease-specific therapies for pediatric cardiomyopathies are in

162 The development of disease-specific therapies for pulmonary arterial hypertension o

163 There are currently no specific therapies for STEC-associated HUS, and the mech

164 Specific therapies for symptomatic patient types are mor

165 301L mutant, indicating the need for disease-specific therapies for tauopathies.

166 findings might help to develop novel antigen-specific therapies for the treatment of allergy and auto

167 ay could facilitate the development of novel specific therapies for the treatment of painful PDN.

168 ir known or suspected infections and without specific therapies for their glomerulonephritis, includi

169 afferents that could be exploited to design specific therapies for visceral hypersensitivity.

170 o-called "augmentation therapy"-represents a specific therapy for AAT deficiency and raises serum lev

171 presents an important step toward an antigen-specific therapy for anti-MAG neuropathy.

172 No specific therapy for any human coronavirus is available,

173 and support translation of PMT as the first specific therapy for children with hPAP.

174 There is no specific therapy for electrical injury, and the manageme

175 to HSC, potentially allowing tailored, cell-specific therapy for HCC.

176 There is no specific therapy for HS.

177 immunogenic DCs can be engineered for myelin-specific therapy for MS.

178 nly biomarker established for selection of a specific therapy for patients with advanced gastroesopha

179 used tumor profiling results to direct site-specific therapy for patients with CUP.

180 There is no effective disease-specific therapy for poststreptococcal glomerulonephriti

181 Even though a specific therapy for SMA is not currently available, a n

182 lass II chimera aimed at devising an antigen-specific therapy for suppression of anti-islet T cell re

183 Currently there is no approved vaccine or specific therapy for the disease.

184 suggest targets for the development of more specific therapy for these common rhythm disturbances.

185 At present, there is no specific therapy for VLS.

186 been some of the earliest targets for tumor-specific therapy, for example, the estrogen receptor in

187 Yet to date, no eIF4E-specific therapy has been developed.

188 However, no specific therapy has been suggested to ameliorate the ne

189 ully determined to the point where mechanism-specific therapies have been developed.

190 treatment, yet the mechanisms of response to specific therapies have been largely unexplored in vivo.

191 breast cancer is a heterogeneous disease and specific therapies have not been available for a long ti

192 adult studies provide the basis for most PAH-specific therapies; however, many of these medications a

193 intensive care unit, until very recently no specific therapies improved outcome after intracerebral

194 es using the PEC-rtTA mouse may lead to more specific therapies in AKI.

195 However, clinical translation of antigen-specific therapies in general is hampered by the lack of

196 t possible to take full advantage of peptide-specific therapies in modulating T cell responses.

197 hould be considered in the development of Ag-specific therapies in MS.

198 w this could lead to the development of more specific therapies in the future.

199 ergic asthma that might help to develop more specific therapies in the future.

200 s will, it is hoped, enable the targeting of specific therapies in wound healing, both to effect scar

201 d that vitamin E may be considered as a NASH-specific therapy in children, and there are several ongo

202 research regarding the use of HIV-1- and HCV-specific therapy in coinfected individuals.

203 Demonstration of efficacious antigen-specific therapy in multiple sclerosis.

204 sible for this condition will guide genotype-specific therapy in the near future.

205 resulted in an unmet clinical need for cell-specific therapy in the treatment of FSGS and other prot

206 and has implications for the use of antigen-specific therapy in tolerance induction.

207 refining diagnoses and matching patients to specific therapies, in some cases with dramatic response

208 In this study, we developed an antigen-specific therapy, insulin-coupled antigen-presenting cel

209 risk of complications associated with device-specific therapies is also an important component of the

210 No specific therapy is available, and care is generally sup

211 genesis of CIP is not well understood and no specific therapy is available.

212 centage of DCMs remains unknown, and no gene-specific therapy is available.

213 Specific therapy is not available for hantavirus cardiop

214 Specific therapy is not available for the treatment of h

215 The ability to predict response to a specific therapy is particularly important for medicatio

216 Pathway-specific therapy is the future of cancer management.

217 ors involved in control of WNV infection, no specific therapy is yet available.

218 for depression, and the development of more specific therapies, is limited by the complexity of the

219 In certain instances, specific therapies may ameliorate the neuropathy.

220 Q1347H, and R1314W), suggesting that allele-specific therapy may be useful for selected patients wit

221 In this regard, myelin-specific therapy may provide the desired specificity and

222 urate diagnosis is imperative since delay in specific therapy may result in death.

223 Second, the response to specific therapy must be noted to determine the cause or

224 isabilities after treatment, therefore, more specific therapies need to be developed.

225 When specific therapies no longer exist, palliative intervent

226 Conclusion: Specific therapies of AKI depend on the most likely caus

227 treatment as a promising strategy for allele-specific therapy of ABCC6-associated calcification disor

228 d in veterinary practice for the control and specific therapy of infections in swine.

229 ic progenitor cells in vitro and for antigen-specific therapy of leukemia and other WT1-expressing ma

230 A vaccination may offer a new approach to Ag-specific therapy of uveitis.

231 These observations may indicate that epitope-specific therapies operate at the level of regulating me

232 fy high-risk children who might benefit from specific therapies or secondary prevention interventions

233 No specific therapies or vaccines are available for LACV or

234 t may identify patients likely to respond to specific therapy or having a high probability of relapse

235 Currently, no specific therapy or treatment is available to improve pl

236 disease in humans globally, and currently no specific therapy or vaccine is available.

237 ent for WNV infections is supportive, and no specific therapy or vaccine is available.

238 Due to the lack of disease-specific therapies, perioperative management is preventi

239 We have recently developed a cancer-specific therapy, photoimmunotherapy, which uses an anti

240 patient subgroups, selection of patients for specific therapies, prediction of risk for toxicities to

241 Will it even be possible to design specific therapy protocols for all MDs?

242 ction was confirmed based on the response to specific therapy regardless of culture results.

243 What specific therapy should be instituted and which are the

244 during the course of disease, single-epitope-specific therapies show considerable efficacy in multi-e

245 EPICUP diagnoses who received a tumour type-specific therapy showed improved overall survival compar

246 se they influence prophylactic, empiric, and specific therapy strategies.

247 ment of invasive therapies and novel disease-specific therapies, strategies for patient enrichment in

248 his is critically important when deciding on specific therapies such as corticosteroids or when inter

249 As a result, more specific therapies tailored toward prognostic subgroups

250 dentification of critical genes involved and specific therapies targeted to correct these defects.

251 ups of GBM with the hope of developing tumor specific therapies targeted to the unique biology within

252 recluded in vivo proof-of-concept studies of specific therapies targeting IgA1.

253 es should investigate diagnostic- and gender-specific therapies targeting the neural systems implicat

254 provide a foundation for developing a cancer-specific therapy targeting BMI1.

255 preclinical safety and efficacy of a disease-specific therapy targeting the central oncogenic driver

256 In addition, we summarize effective specific therapies tested across major autoimmune diseas

257 profiles had better response to colon cancer-specific therapies than they did to empiric CUP therapy

258 ics are increasingly complemented by pathway-specific therapies that aim to correct the consequences

259 umor biology but also for the development of specific therapies that effectively target these cells i

260 that stimulate immune responses, and antigen-specific therapies that induce tolerance to self antigen

261 nt the mechanisms of ECD should lead to more specific therapies that may ameliorate the continuing la

262 h implications for prognosis and response to specific therapies that may provide insight into mechani

263 ratification and for the development of gene-specific therapies that may reduce the risk of life-thre

264 ause early diagnosis may lead to instituting specific therapy that may prolong survival, improve qual

265 There is no specific therapy that reduces organ injury/dysfunction.

266 There is no specific therapy that reduces organ injury/dysfunction.

267 tudy, we identified a potential novel myelin-specific therapy that works with immunogenic DCs, hence

268 merging for the identification of mutant p53-specific therapies, therapies targeted at mutant p53-exp

269 ment of HUS remains supportive; there are no specific therapies to ameliorate the course.

270 he underlying pathological process, allowing specific therapies to be started.

271 enesis can be helpful for the development of specific therapies to counteract DS in a timely manner.

272 As a result, specific therapies to halt or even reverse fibrosis have

273 A major goal of cancer research is to match specific therapies to molecular targets in cancer.

274 ations for the use and monitoring of insulin-specific therapies to prevent diabetes onset.

275 ; this will allow for the rational design of specific therapies to prevent or ameliorate this serious

276 Currently there are no approved vaccines or specific therapies to prevent or treat Zika virus (ZIKV)

277 ear, it will perhaps be possible to use more specific therapies to prevent their production and ultim

278 he routine detection of resistance to tailor specific therapies to the patient.

279 e multivariable associations may help target specific therapies to those at the greatest risk of sudd

280 To date, there are no antiviral drugs or specific therapies to treat MERS-CoV.

281 s resulted in the advance of the first eIF4E-specific therapy to clinical trials.

282 techniques may allow development of patient-specific therapy to improve outcome in patients with gli

283 autoantigen illustrates the requirement for specific therapy to induce dominant forms of tolerance,

284 ic perturbations are recognized as requiring specific therapy to reduce complications (such as for an

285 This study documents the first specific therapy, to our knowledge, for lowering apo(a)/

286 When stratified by specific therapy, treatment failures increased consisten

287 types, recurrence of disease and response to specific therapies using DNA microarray-based gene expre

288 f GPs treated at least one patient with site-specific therapy using chemotherapeutic agents.

289 he chromosomal abnormality that defines CML, specific therapy was developed, initially with imatinib

290 The responses to specific therapies were also sexually dimorphic.

291 onia, 27.6% of physicians preferred pathogen-specific therapy, whereas the remainder (72.4%) selected

292 The development of these process-specific therapies will be impossible without the use of

293 r cancer therapies, as well as novel subtype-specific therapies, will be of interest.

294 ight eventually offer the potential to match specific therapies with individual patients based on a f

295 cer is a prerequisite to ultimately matching specific therapies with individual patients.

296 he development of optogenetically based cell-specific therapies with which to treat neurological dise

297 This highly efficient antigen-specific therapy with a complete avoidance of immunosupp

298 These studies identify a strategy for tumor-specific therapy with CAR-modified T cells after allo-HS

299 Specific therapy with somatostatin analogues (octreotide

300 genetically diverse disorder, such that gene-specific therapies would be practical in a small fractio